Cargando…

Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial

Objective: This subanalysis of the VIVEVE I trial aimed to evaluate the impact of cryogen-cooled monopolar radiofrequency (CMRF) therapy, for the treatment of vaginal laxity, on the domains of sexual function included in the Female Sexual Function Index (FSFI). Materials and Methods: The VIVEVE I cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Krychman, Michael, Rowan, Christopher G., Allan, Bruce B., Durbin, Scott, Yacoubian, Ashley, Wilkerson, Deborah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865245/
https://www.ncbi.nlm.nih.gov/pubmed/29182498
http://dx.doi.org/10.1089/jwh.2017.6335
_version_ 1783308645117722624
author Krychman, Michael
Rowan, Christopher G.
Allan, Bruce B.
Durbin, Scott
Yacoubian, Ashley
Wilkerson, Deborah
author_facet Krychman, Michael
Rowan, Christopher G.
Allan, Bruce B.
Durbin, Scott
Yacoubian, Ashley
Wilkerson, Deborah
author_sort Krychman, Michael
collection PubMed
description Objective: This subanalysis of the VIVEVE I trial aimed to evaluate the impact of cryogen-cooled monopolar radiofrequency (CMRF) therapy, for the treatment of vaginal laxity, on the domains of sexual function included in the Female Sexual Function Index (FSFI). Materials and Methods: The VIVEVE I clinical trial was prospective, randomized, single-blind, and Sham-controlled. Nine clinical study centers in Canada, Italy, Spain, and Japan were included. This subanalysis included premenopausal women with self-reported vaginal laxity who had ≥1 term vaginal delivery and a baseline FSFI total score ≤26.5, indicating sexual dysfunction. Enrolled subjects were randomized (2:1) to receive CMRF therapy [Active (90 J/cm(2)) vs. Sham (≤1 J/cm(2))] delivered to the vaginal tissue. Independent analyses were conducted for each FSFI domain to evaluate both the mean change, as well as the clinically important change for Active- versus Sham-treated subjects at 6 months post-intervention. Results: Subjects randomized to Active treatment (n = 73) had greater improvement than Sham subjects (n = 35) on all FSFI domains of sexual function at 6 months postintervention. The analysis of covariance change from baseline analyses showed statistically significant improvements, in favor of Active treatment, for sexual arousal (p = 0.004), lubrication (p = 0.04), and orgasm (p = 0.007). In addition, Active treatment was associated with clinically important and statistically significant improvements in sexual desire [Odds ratio (OR) = 3.01 (1.11–8.17)], arousal [OR = 2.73 (1.06–7.04)], and orgasm [OR = 2.58 (1.08–6.18)]. Conclusions: This subanalysis showed CMRF therapy is associated with statistically significant and clinically important improvements in sexual function in women with vaginal laxity. These findings provide the first randomized, placebo-controlled energy-based device evidence for functional improvements associated with a nonsurgical modality for a highly prevalent and undertreated condition.
format Online
Article
Text
id pubmed-5865245
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Mary Ann Liebert, Inc.
record_format MEDLINE/PubMed
spelling pubmed-58652452018-03-27 Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial Krychman, Michael Rowan, Christopher G. Allan, Bruce B. Durbin, Scott Yacoubian, Ashley Wilkerson, Deborah J Womens Health (Larchmt) Original Articles Objective: This subanalysis of the VIVEVE I trial aimed to evaluate the impact of cryogen-cooled monopolar radiofrequency (CMRF) therapy, for the treatment of vaginal laxity, on the domains of sexual function included in the Female Sexual Function Index (FSFI). Materials and Methods: The VIVEVE I clinical trial was prospective, randomized, single-blind, and Sham-controlled. Nine clinical study centers in Canada, Italy, Spain, and Japan were included. This subanalysis included premenopausal women with self-reported vaginal laxity who had ≥1 term vaginal delivery and a baseline FSFI total score ≤26.5, indicating sexual dysfunction. Enrolled subjects were randomized (2:1) to receive CMRF therapy [Active (90 J/cm(2)) vs. Sham (≤1 J/cm(2))] delivered to the vaginal tissue. Independent analyses were conducted for each FSFI domain to evaluate both the mean change, as well as the clinically important change for Active- versus Sham-treated subjects at 6 months post-intervention. Results: Subjects randomized to Active treatment (n = 73) had greater improvement than Sham subjects (n = 35) on all FSFI domains of sexual function at 6 months postintervention. The analysis of covariance change from baseline analyses showed statistically significant improvements, in favor of Active treatment, for sexual arousal (p = 0.004), lubrication (p = 0.04), and orgasm (p = 0.007). In addition, Active treatment was associated with clinically important and statistically significant improvements in sexual desire [Odds ratio (OR) = 3.01 (1.11–8.17)], arousal [OR = 2.73 (1.06–7.04)], and orgasm [OR = 2.58 (1.08–6.18)]. Conclusions: This subanalysis showed CMRF therapy is associated with statistically significant and clinically important improvements in sexual function in women with vaginal laxity. These findings provide the first randomized, placebo-controlled energy-based device evidence for functional improvements associated with a nonsurgical modality for a highly prevalent and undertreated condition. Mary Ann Liebert, Inc. 2018-03-01 2018-03-01 /pmc/articles/PMC5865245/ /pubmed/29182498 http://dx.doi.org/10.1089/jwh.2017.6335 Text en © Michael Krychman et al. 2018; Published byMary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are cited.
spellingShingle Original Articles
Krychman, Michael
Rowan, Christopher G.
Allan, Bruce B.
Durbin, Scott
Yacoubian, Ashley
Wilkerson, Deborah
Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
title Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
title_full Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
title_fullStr Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
title_full_unstemmed Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
title_short Effect of Single-Session, Cryogen-Cooled Monopolar Radiofrequency Therapy on Sexual Function in Women with Vaginal Laxity: The VIVEVE I Trial
title_sort effect of single-session, cryogen-cooled monopolar radiofrequency therapy on sexual function in women with vaginal laxity: the viveve i trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865245/
https://www.ncbi.nlm.nih.gov/pubmed/29182498
http://dx.doi.org/10.1089/jwh.2017.6335
work_keys_str_mv AT krychmanmichael effectofsinglesessioncryogencooledmonopolarradiofrequencytherapyonsexualfunctioninwomenwithvaginallaxitytheviveveitrial
AT rowanchristopherg effectofsinglesessioncryogencooledmonopolarradiofrequencytherapyonsexualfunctioninwomenwithvaginallaxitytheviveveitrial
AT allanbruceb effectofsinglesessioncryogencooledmonopolarradiofrequencytherapyonsexualfunctioninwomenwithvaginallaxitytheviveveitrial
AT durbinscott effectofsinglesessioncryogencooledmonopolarradiofrequencytherapyonsexualfunctioninwomenwithvaginallaxitytheviveveitrial
AT yacoubianashley effectofsinglesessioncryogencooledmonopolarradiofrequencytherapyonsexualfunctioninwomenwithvaginallaxitytheviveveitrial
AT wilkersondeborah effectofsinglesessioncryogencooledmonopolarradiofrequencytherapyonsexualfunctioninwomenwithvaginallaxitytheviveveitrial